Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999681099> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2999681099 abstract "ABSTRACT Background Addition of bevacizmab (BEV) to platinum-based doublet yields a significant but only modest survival advantage. Recently, in the PARAMOUNT trial pemetrexed (PEM) maintenance therapy produced a high magnitude of PFS improvement. The OLCSG 0903 phase 2 trial investigated efficacy and safety of cisplatin (CDDP)-docetaxel (DOC)-BEV induction therapy followed by BEV-PEM maintenance therapy in patients with advanced nonsquamous non-small cell lung carcinoma. Methods In this trial, 40 patients with good PS (0 or 1) participated in the induction phase, specified as four cycles of induction CDDP (80 mg/m2), DOC (60 mg/m2) and BEV (15 mg/kg) on day 1 of a 21-day cycle. Patients who had not progressed during CDDP-DOC-BEV induction received maintenance BEV (15 mg/kg) and PEM (500 mg/m2) on day 1 of a 21-day cycle until disease progression. The primary endpoint was PFS, and the secondary endpoints included toxicity, OS and response rate. Results Patient characteristics were as follows: median age: 62 years; 78% male; 100% Japanese; 30% PS 0; 73% stage IV; and 70% adenocarcinoma. At the time of this analysis, 23pts (58%) discontinued the treatment, and the proportion of discontinuations to AEs was 35% (8/23). The principal toxicity was myelosuppression (grade 4 hematological: 20 patients [50%]), and grade 3/4 febrile neutropenia was observed in 10 (25%) despite no treatment-related deaths. The objective response rate and disease control rate (% patients with CR/PR/SD) was 82.5% and 97.5%, respectively. The median PFS time was 10.2 months, and the 6-month PFS rate was 63.2% (95% confidence interval: 44.9-76.9 %). Conclusions CDDP-DOC-BEV followed by BEV-PEM maintenance seems an effective and moderately tolerated treatment for patients with advanced nonsquamous non-small cell lung carcinoma. Disclosure K. Hotta: Eli Lilly Japan sanofi-aventis Chugai Pharmaceutical Co. Ltd Nippon Kayaku. N. Takigawa: Eli Lilly Japan sanofi-aventis Chugai Pharmaceutical Co. Ltd. K. Kiura: Eli Lilly Japan sanofi-aventis Chugai Pharmaceutical Co. Ltd Nippon Kayaku. All other authors have declared no conflicts of interest." @default.
- W2999681099 created "2020-01-23" @default.
- W2999681099 creator A5001897650 @default.
- W2999681099 creator A5007888883 @default.
- W2999681099 creator A5011349417 @default.
- W2999681099 creator A5034733511 @default.
- W2999681099 creator A5042110139 @default.
- W2999681099 creator A5052312623 @default.
- W2999681099 creator A5062920555 @default.
- W2999681099 creator A5066700160 @default.
- W2999681099 creator A5071084888 @default.
- W2999681099 creator A5074862416 @default.
- W2999681099 date "2012-09-01" @default.
- W2999681099 modified "2023-09-30" @default.
- W2999681099 title "A Phase II Trial of Cisplatin-Docetaxel-Bevacizmab Induction Chemotherapy Followed by Bevacizmab and Pemetrexed Maintenance Therapy in Patients with Nonsquamous Cell Lung Carcinoma: Okayama Lung Cancer Study Group Trial 0903" @default.
- W2999681099 doi "https://doi.org/10.1016/s0923-7534(20)33788-1" @default.
- W2999681099 hasPublicationYear "2012" @default.
- W2999681099 type Work @default.
- W2999681099 sameAs 2999681099 @default.
- W2999681099 citedByCount "1" @default.
- W2999681099 countsByYear W29996810992018 @default.
- W2999681099 crossrefType "journal-article" @default.
- W2999681099 hasAuthorship W2999681099A5001897650 @default.
- W2999681099 hasAuthorship W2999681099A5007888883 @default.
- W2999681099 hasAuthorship W2999681099A5011349417 @default.
- W2999681099 hasAuthorship W2999681099A5034733511 @default.
- W2999681099 hasAuthorship W2999681099A5042110139 @default.
- W2999681099 hasAuthorship W2999681099A5052312623 @default.
- W2999681099 hasAuthorship W2999681099A5062920555 @default.
- W2999681099 hasAuthorship W2999681099A5066700160 @default.
- W2999681099 hasAuthorship W2999681099A5071084888 @default.
- W2999681099 hasAuthorship W2999681099A5074862416 @default.
- W2999681099 hasBestOaLocation W29996810991 @default.
- W2999681099 hasConcept C126322002 @default.
- W2999681099 hasConcept C141071460 @default.
- W2999681099 hasConcept C143998085 @default.
- W2999681099 hasConcept C203092338 @default.
- W2999681099 hasConcept C2776256026 @default.
- W2999681099 hasConcept C2776611710 @default.
- W2999681099 hasConcept C2776694085 @default.
- W2999681099 hasConcept C2776907518 @default.
- W2999681099 hasConcept C2777063308 @default.
- W2999681099 hasConcept C2777240266 @default.
- W2999681099 hasConcept C2778239845 @default.
- W2999681099 hasConcept C2778283404 @default.
- W2999681099 hasConcept C2778822529 @default.
- W2999681099 hasConcept C2778850193 @default.
- W2999681099 hasConcept C2780739268 @default.
- W2999681099 hasConcept C2781190966 @default.
- W2999681099 hasConcept C31760486 @default.
- W2999681099 hasConcept C535046627 @default.
- W2999681099 hasConcept C71924100 @default.
- W2999681099 hasConceptScore W2999681099C126322002 @default.
- W2999681099 hasConceptScore W2999681099C141071460 @default.
- W2999681099 hasConceptScore W2999681099C143998085 @default.
- W2999681099 hasConceptScore W2999681099C203092338 @default.
- W2999681099 hasConceptScore W2999681099C2776256026 @default.
- W2999681099 hasConceptScore W2999681099C2776611710 @default.
- W2999681099 hasConceptScore W2999681099C2776694085 @default.
- W2999681099 hasConceptScore W2999681099C2776907518 @default.
- W2999681099 hasConceptScore W2999681099C2777063308 @default.
- W2999681099 hasConceptScore W2999681099C2777240266 @default.
- W2999681099 hasConceptScore W2999681099C2778239845 @default.
- W2999681099 hasConceptScore W2999681099C2778283404 @default.
- W2999681099 hasConceptScore W2999681099C2778822529 @default.
- W2999681099 hasConceptScore W2999681099C2778850193 @default.
- W2999681099 hasConceptScore W2999681099C2780739268 @default.
- W2999681099 hasConceptScore W2999681099C2781190966 @default.
- W2999681099 hasConceptScore W2999681099C31760486 @default.
- W2999681099 hasConceptScore W2999681099C535046627 @default.
- W2999681099 hasConceptScore W2999681099C71924100 @default.
- W2999681099 hasLocation W29996810991 @default.
- W2999681099 hasOpenAccess W2999681099 @default.
- W2999681099 hasPrimaryLocation W29996810991 @default.
- W2999681099 hasRelatedWork W1964370859 @default.
- W2999681099 hasRelatedWork W1974280424 @default.
- W2999681099 hasRelatedWork W2040253672 @default.
- W2999681099 hasRelatedWork W2082547513 @default.
- W2999681099 hasRelatedWork W2122311431 @default.
- W2999681099 hasRelatedWork W2152237079 @default.
- W2999681099 hasRelatedWork W2235272930 @default.
- W2999681099 hasRelatedWork W2276827064 @default.
- W2999681099 hasRelatedWork W2349790989 @default.
- W2999681099 hasRelatedWork W2589833400 @default.
- W2999681099 hasRelatedWork W2604248486 @default.
- W2999681099 hasRelatedWork W2945202946 @default.
- W2999681099 hasRelatedWork W2996211065 @default.
- W2999681099 hasRelatedWork W2998990041 @default.
- W2999681099 hasRelatedWork W2999324305 @default.
- W2999681099 hasRelatedWork W2999619211 @default.
- W2999681099 hasRelatedWork W2999684312 @default.
- W2999681099 hasRelatedWork W3000022437 @default.
- W2999681099 hasRelatedWork W3000198496 @default.
- W2999681099 hasRelatedWork W3210251887 @default.
- W2999681099 isParatext "false" @default.
- W2999681099 isRetracted "false" @default.
- W2999681099 magId "2999681099" @default.
- W2999681099 workType "article" @default.